The potential of stem cells in the treatment of skeletal muscle injury and disease

S Maclean, W S Khan, A A Malik, S Anand, M Snow, S Maclean, W S Khan, A A Malik, S Anand, M Snow

Abstract

Tissue engineering is a pioneering field with huge advances in recent times. These advances are not only in the understanding of how cells can be manipulated but also in potential clinical applications. Thus, tissue engineering, when applied to skeletal muscle cells, is an area of huge prospective benefit to patients with muscle disease/damage. This could include damage to muscle from trauma and include genetic abnormalities, for example, muscular dystrophies. Much of this research thus far has been focused on satellite cells, however, mesenchymal stem cells have more recently come to the fore. In particular, results of trials and further research into their use in heart failure, stress incontinence, and muscular dystrophies are eagerly awaited. Although no doubt, stem cells will have much to offer in the future, the results of further research still limit their use.

Figures

Figure 1
Figure 1
Cell surface epitope characterisation of passage 2 infrapatellar fat-pad-derived stem cells using a panel of antibodies. Cell surface staining using FITC-conjugated secondary antibody (green) and DAPI (blue) shows that the cells stain strongly for CD13, 29, 44, 90, and 105, and poorly for 3G5, LNGFR, STRO-1, and CD34 and 56. No staining was observed for the IgG control. The staining pattern is confirmed by flow cytometry and shows the increase in fluorescence (green) compared with the autofluorescence (black) [21].

References

    1. Cetinus E, Uzel M, Bilgiç E, Karaoguz A, Herdem M. Exercise induced compartment syndrome in a professional footballer. British Journal of Sports Medicine. 2004;38(2):227–229.
    1. Shen W, Li Y, Tang Y, Cummins J, Huard J. NS-398, a cyclooxygenase-2-specific inhibitor, delays skeletal muscle healing by decreasing regeneration and promoting fibrosis. American Journal of Pathology. 2005;167(4):1105–1117.
    1. Li Y, Huard J. Differentiation of muscle-derived cells into myofibroblasts in injured skeletal muscle. American Journal of Pathology. 2002;161(3):895–907.
    1. Ghosh AK. Factors involved in the regulation of type I collagen gene expression: iimplication in fibrosis. Experimental Biology and Medicine. 2002;227(5):301–314.
    1. Cortes E, Te Fong LF, Hameed M, et al. Insulin-like growth factor-1 gene splice variants as markers of muscle damage in levator ani muscle after the first vaginal delivery. American Journal of Obstetrics and Gynecology. 2005;193(1):64–70.
    1. Foster W, Li Y, Usas A, Somogyi G, Huard J. Gamma interferon as an antifibrosis agent in skeletal muscle. Journal of Orthopaedic Research. 2003;21(5):798–804.
    1. Fukushima K, Badlani N, Usas A, Riano F, Fu FH, Huard J. The use of an antifibrosis agent to improve muscle recovery after laceration. American Journal of Sports Medicine. 2001;29(4):394–402.
    1. Kloen P, Jennings CL, Gebhardt MC, Springfield DS, Mankin HJ. Suramin inhibits growth and transforming growth factor-β1 (TGF-β1) binding in osteosarcoma cell lines. European Journal of Cancer A. 1994;30(5):678–682.
    1. Cossu G, Sampaolesi M. New therapies for Duchenne muscular dystrophy: challenges, prospects and clinical trials. Trends in Molecular Medicine. 2007;13(12):520–526.
    1. Lee EH, Hui JHP. The potential of stem cells in orthopaedic surgery. Journal of Bone and Joint Surgery B. 2006;88(7):841–851.
    1. Bongso A, Lee EH. Stem cells: their definition, classification and sources. In: Bongso A, Lee EH, editors. Stem Cells: From Bench to Bedside. Singapore: World Scientific; 2005. pp. 1–14.
    1. Mauro A. Satellite cell of skeletal muscle fibers. The Journal of Biophysical and Biochemical Cytology. 1961;9:493–495.
    1. Seale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, Gruss P, Rudnicki MA. Pax7 is required for the specification of myogenic satellite cells. Cell. 2000;102(6):777–786.
    1. Kuang S, Kuroda K, Le Grand F, Rudnicki MA. Asymmetric self-renewal and commitment of satellite stem cells in muscle. Cell. 2007;129(5):999–1010.
    1. Collins CA, Olsen I, Zammit PS, et al. Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. Cell. 2005;122(2):289–301.
    1. Kottlors M, Kirschner J. Elevated satellite cell number in Duchenne muscular dystrophy. Cell and Tissue Research. 2010;340(3):541–548.
    1. Yaffe D. Retention of differentiation potentialities during prolonged cultivation of myogenic cells. Proceedings of the National Academy of Sciences of the United States of America. 1968;61(2):477–483.
    1. Bhagavati S, Xu W. Generation of skeletal muscle from transplanted embryonic stem cells in dystrophic mice. Biochemical and Biophysical Research Communications. 2005;333(2):644–649.
    1. Cossu G, Sampaolesi M. New therapies for muscular dystrophy: cautious optimism. Trends in Molecular Medicine. 2004;10(10):516–520.
    1. Tedesco FS, Dellavalle A, Diaz-Manera J, Messina G, Cossu G. Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. Journal of Clinical Investigation. 2010;120(1):11–19.
    1. Khan WS, Adesida AB, Hardingham TE. Hypoxic conditions increase HIF2a and enhance chondrogenesis in stem cells from the infrapatellar fat pad of osteoarthritic patients. Arthritis Research and Therapy. 2007;9, article R55
    1. Ferrari G, Cusella-De Angelis G, Coletta M, et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science. 1998;279(5356):1528–1530.
    1. Gussoni E, Soneoka Y, Strickland CD, et al. Allogenic mesoangioblasts give rise to alpha-sarcoglycan expressing fibers when transplanted into dystrophic mice. Experimental Cell Research. 2006;312(19):3872–3879.
    1. Sampaolesi M, Torrente Y, Innocenzi A, et al. Cell therapy of α-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science. 2003;301(5632):487–492.
    1. Dellavalle A, Sampaolesi M, Tonlorenzi R, et al. Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nature Cell Biology. 2007;9(3):255–267.
    1. Brazelton TR, Nystrom M, Blau HM. Significant differences among skeletal muscles in the incorporation of bone marrow-derived cells. Developmental Biology. 2003;262(1):64–74.
    1. Meirelles LS, Nardi NB. Methodology, biology and clinical applications of mesenchymal stem cells. Frontiers in Bioscience. 2009;14:4281–4298.
    1. Otto A, Collins-Hooper H, Patel K. The origin, molecular regulation and therapeutic potential of myogenic stem cell populations. Journal of Anatomy. 2009;215(5):477–497.
    1. Beier JP, Horch RE, Bach AD. Tissue engineering of skeletal muscle. Minerva Biotecnologica. 2006;18(2):89–96.
    1. Merritt EK, Cannon MV, Hammers DW, et al. Repair of traumatic skeletal muscle injury with bone-marrow-derived mesenchymal stem cells seeded on extracellular matrix. Tissue Engineering A. 2010;16(9):2871–2881.
    1. Huang NF, Thakar RG, Wong M, Kim D, Lee RJ, Li S. Tissue engineering of muscle on micropatterned polymer films. In: Proceedings of the 26th Annual International Conference of the IEEE Engineering in Medicine and Biology Society; September 2004; pp. 4966–4969.
    1. Barnes CP, Sell SA, Boland ED, Simpson DG, Bowlin GL. Nanofiber technology: designing the next generation of tissue engineering scaffolds. Advanced Drug Delivery Reviews. 2007;59(14):1413–1433.
    1. Dennis RG, Kosnik PE, II, Gilbert ME, Faulkner JA. Excitability and contractility of skeletal muscle engineered from primary cultures and cell lines. American Journal of Physiology. 2001;280(2):C288–C295.
    1. Telemeco TA, Ayres C, Bowlin GL, et al. Regulation of cellular infiltration into tissue engineering scaffolds composed of submicron diameter fibrils produced by electrospinning. Acta Biomaterialia. 2005;1(4):377–385.
    1. Koning M, Harmsen MC, Van Luyn MJA, Werker PMN. Current opportunities and challenges in skeletal muscle tissue engineering. Journal of Tissue Engineering and Regenerative Medicine. 2009;3(6):407–415.
    1. Saxena AK, Willital GH, Vacanti JP, et al. Vascularised three-dimensional skeletal muscle tissue-engineeering. Biomedical Engineering Masters. 2001;111(4):275–281.
    1. Singh D, Nayak V, Kumar A. Proliferation of myoblast skeletal cells on three-dimensional supermacroporous cryogels. International Journal of Biological Sciences. 2010;6(4):371–381.
    1. Sekine H, Shimizu T, Yang J, Kobayashi E, Okano T. Pulsatile myocardial tubes fabricated with cell sheet engineering. Circulation. 2006;114(1):I87–I93.
    1. Yan W, George S, Fotadar U, et al. Tissue engineering of skeletal muscle. Tissue Engineering. 2007;13(11):2781–2790.
    1. Beier JP, Kneser U, Stern-Strater J, Stark GB, Bach AD. Y chromosome detection of three-dimensional tissue-engineered skeletal muscle constructs in a syngeneic rat animal model. Cell Transplantation. 2004;13(1):45–53.
    1. Duffy GP, McFadden TM, Byrne EM, et al. Towards in vitro vascularisation of collagen-GAG scaffolds. European Cells & Materials. 2011;12(21):15–30.
    1. Wilschut KJ, Haagsman HP, Roelen BA. Extracellular matrix components direct porcine muscle stem cell behavior. Experimental Cell Research. 2010;316(3):341–352.
    1. Law PK, Goodwin TG, Fang QW, et al. Myoblast transfer therapy for Duchenne muscular dystrophy. Acta Paediatrica Japonica. 1991;33(2):206–215.
    1. Law PK, Goodwin TG, Fang Q, et al. Feasibility, safety, and efficacy of myoblast transfer therapy on Duchenne muscular dystrophy boys. Cell Transplantation. 1992;1(2-3):235–244.
    1. Karpati G, Ajdukovic D, Arnold D, et al. Myoblast transfer in Duchenne muscular dystrophy. Annals of Neurology. 1993;34(1):8–17.
    1. Tremblay JP, Malouin F, Roy R, et al. Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplantation. 1993;2(2):99–112.
    1. Mendell JR, Kissel JT, Amato AA, et al. Myoblast transfer in the treatment of Duchenne’s muscular dystrophy. The New England Journal of Medicine. 1995;333(13):832–838.
    1. Neumeyer AM, Cros D, McKenna-Yasek D, et al. Pilot study of myoblast transfer in the treatment of Becker muscular dystrophy. Neurology. 1998;51(2):589–592.
    1. Skuk D, Goulet M, Tremblay JP. Use of repeating dispensers to increase the efficiency of the intramuscular myogenic cell injection procedure. Cell Transplantation. 2006;15(7):659–663.
    1. Cossu G, Sampaolesi M. New therapies for Duchenne muscular dystrophy: challenges, prospects and clinical trials. Trends in Molecular Medicine. 2007;13(12):520–526.
    1. Gussoni E, Soneoka Y, Strickland CD, et al. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature. 1999;401(6751):390–394.
    1. Cassano M, Biressi S, Finan A, et al. Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis. Plos One. 2008;3(9) Article ID e3223.
    1. Torrente Y, Belicchi M, Marchesi C, et al. Autologous transplantation of muscle-derived CD133+ stem cells in Duchenne muscle patients. Cell Transplantation. 2007;16(6):563–577.
    1. Duckers HJ, Houtgraaf J, Hehrlein C, et al. Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial. EuroIntervention. 2011;6(7):805–812.
    1. Menasche P, Alfieri O, Janssens S, et al. The myoblast autologous grafting in ischemic cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation. 2008;117(9):1189–1200.
    1. Lainscak M, Coletta AP, Sherwi N, Cleland JGF. Clinical trials update from the heart failure society of America meeting 2009: FAST, IMPROVE-HF, COACH galectin-3 substudy, HF-ACTION nuclear substudy, DAD-HF, and MARVEL-1. European Journal of Heart Failure. 2010;12(2):193–196.
    1. Dambrot C, Passier R, Atsma D, et al. Cardiomyocyte differentiation of pluripotent stem cells and their use as cardiac disease models. Biochemical Journal. 2011;434(1):25–35.
    1. Proano AR, Medrano A, Garrido G, Mazza O. Muscle-derived stem cell therapy for stress urinary incontinence. Actas Urologicas Espanolas. 2010;34(1):15–23.
    1. Frauscher F, Helweg G, Strasser H, et al. Intraurethral ultrasound: diagnostic evaluation of the striated urethral sphincter in incontinent females. European Radiology. 1998;8(1):50–53.
    1. Mitterberger M, Pinggera GM, Marksteiner R, et al. Adult stem cell therapy of female stress urinary incontinence. European Urology. 2008;53(1):169–175.
    1. Strasser H, Marksteiner R, Margreiter E, et al. Autologous myoblasts and fibroblasts versus collagen for treatment of stress urinary incontinence in women: a randomised controlled trial. The Lancet. 2007;369(9580):2179–2186.
    1. Mitterberger M, Marksteiner R, Margreiter E, et al. Autologous myoblasts and fibroblasts for female stress incontinence: a 1-year follow-up in 123 patients. British Journal of Urology International. 2007;100(5):1081–1085.
    1. Strasser H, Marksteiner R, Margreiter E, et al. Transurethral ultrasonography-guided injection of adult autologous stem cells versus transurethral endoscopic injection of collagen in treatment of urinary incontinence. World Journal of Urology. 2007;25(4):385–392.
    1. Yamamoto T, Gotoh M, Hattori R, et al. Periurethral injection of autologous adipose-derived stem cells for the treatment of stress urinary incontinence in patients undergoing radical prostatectomy: report of two initial cases: original article: clinical investigations. International Journal of Urology. 2010;17(1):75–82.
    1. Mitterberger M, Marksteiner R, Margreiter E, et al. Myoblast and fibroblast therapy for post-prostatectomy urinary incontinence: 1-year followup of 63 patients. Journal of Urology. 2008;179(1):226–231.
    1. Khan WS, Malik AA, Hardingham TE. Stem cell applications and tissue engineering approaches in surgical practice. Journal of Perioperative Practice. 2009;19(4):130–135.
    1. Khan WS, Marsh DR. A literature review on the effects of ageing on mesenchymal stem cells. Current Research Journal of Biological Sciences. 2009;1(1):1–6.
    1. Nannaparaju M, Oragui E, Khan WS. The role of stem cells, scaffolds and bioreactors in musculoskeletal tissue engineering. In: Xiao Y, editor. Mesenchymal Stem Cells. New York, NY, USA: Nova Science; 2011.
    1. Mahapatra A, Khan WS. Tissue engineering in orthopaedics and musculoskeletal sciences. The Open Orthopaedics Journal. 2011;5(2):239–241.
    1. Mafi P, Hindocha S, Mafi R, Griffin M, Khan WS. Sources of adult mesenchymal stem cells applicable for musculoskeletal applications—a systematic review of the literature. The Open Orthopaedics Journal. 2011;5(2):242–248.
    1. Kennard L, Tailor HD, Thanabalasundaram G, Khan WS. Advances and developments in the use of human mesenchymal stem cells—a few considerations. The Open Orthopaedics Journal. 2011;5:249–252.
    1. Mafi P, Hindocha S, Mafi R, Griffin M, Khan WS. Adult mesenchymal stem cells and cell surface characterization—a systematic review of the literature. The Open Orthopaedics Journal. 2011;5:250–257.
    1. Oragui E, Nannaparaju M, Khan WS. The role of bioreactors in tissue engineering for musculoskeletal applications. The Open Orthopaedics Journal. 2011;5(2):267–270.
    1. Kanitkar M, Tailor HD, Khan WS. The use of growth factors and mesenchymal stem cells in orthopaedics. The Open Orthopaedics Journal. 2011;5(2):268–274.
    1. Malik A, Khan WS. Stem cell applications and tissue engineering approaches in orthopaedic surgery and musculoskeletal medicine. Current Stem Cell Research & Therapy. In press.
    1. Khan WS. Foreword: stem cell applications and tissue engineering approaches in sports medicine—from bench to bedside. Journal of Stem Cells. In press.
    1. Picardo NE, Khan WS. Tissue engineering applications and stem cell approaches to the skin, nerves and blood vessels. Current Stem Cell Research & Therapy. In press.
    1. Tucker BA, Karamsadkar SS, Khan WS, Pastides P. The role of bone marrow derived mesenchymal stem cells in sports injuries. Journal of Stem Cells. In press.
    1. Jaiswal PK, Wong K, Khan WS. Current cell based strategies for knee cartilage injuries. Journal of Stem cells. In press.
    1. Pastides PS, Khan WS. Cell-based therapies in musculoskeletal injuries: the evolving role of bone marrow-derived mesenchymal stem cells. British Journal of Medicine and Medical Research. 2011;1(4):486–500.
    1. Adesida AB, Brady LM, Khan WS, Millward-Sadler JS, Salter DM, Hardingham TE. Human meniscus cells express HIF-1alpha and increased SOX9 in response to low oxygen tension in cell aggregate culture and deposit collagen type I and II in a proteoglycan-deficient matrix. Arthritis Research & Therapy. 2007;9(4, article R69)
    1. Khan WS, Tew SR, Adesida AB, Hardingham TE. Human infrapatellar fat pad-derived stem cells express the pericyte marker 3G5 and show enhanced chondrogenesis after expansion in fibroblast growth factor-2. Arthritis Research and Therapy. 2008;10(4, article R74)
    1. Khan WS, Adesida AB, Tew SR, Andrew JG, Hardingham TE. The epitope characterisation and the osteogenic differentiation potential of human fat pad-derived stem cells is maintained with ageing in later life. Injury. 2009;40(2):150–157.
    1. Khan WS, Hardingham TE. Stem cell applications and cartilage tissue engineering approaches applicable in hand surgery. In: Beckingsworth RH, editor. Hand Surgery: Preoperative Expectations, Techniques and Results. New York, NY, USA: Nova Science; 2009. pp. 1–30.
    1. Khan WS, Rayanmarakkar F, Marsh DR. Principles of tissue engineering approaches for bone repair in the hand. In: Beckingsworth RH, editor. Hand Surgery: Preoperative Expectations, Techniques and Results. New York, NY, USA: Nova Science; 2009. pp. 71–84.
    1. Rayanmarakkar F, Khan WS, Hardingham TE. Principles of tissue engineering approaches for tendons, skin, nerves and blood vessels in the hand. In: Beckingsworth RH, editor. Hand Surgery: Preoperative Expectations, Techniques and Results. New York, NY, USA: Nova Science; 2009. pp. 85–96.
    1. Gidado S, Khan WS, Marsh DR. The effect of changes in oxygen tension during fracture repair on mesenchymal stem cell and bone activities. Current Research Journal of Biological Sciences. 2009;1(1):7–10.
    1. Khan WS, Adesida AB, Tew SR, Lowe ET, Hardingham TE. Bone marrow-derived mesenchymal stem cells express the pericyte marker 3G5 in culture and show enhanced chondrogenesis in hypoxic conditions. Journal of Orthopaedic Research. 2010;28(6):834–840.
    1. Khan WS, Johnson DS, Hardingham DS. The potential use of stem cells for knee articular cartilage repair. Knee. 2010;17(6):369–374.
    1. Punwar S, Khan WS. Mesenchymal stem cells and articular cartilage repair: clinical studies and future direction. The Open Orthopaedics Journal. 2011;5(2):296–301.
    1. Oragui E, Sachinis N, Hope N, Khan WS. Short communication: tendon regeneration and repair, and the role of mesenchymal stem cells. In: Xiao Y, editor. Mesenchymal Stem Cells. New York, NY, USA: Nova Science; 2011.
    1. Baring T, Khan WS, Emery R. Rotator cuff disease: a review of pathophysiology and treatment. In: Berhardt LV, editor. Advances in Medicine and Biology. Vol. 36. New York, NY, USA: Nova Science; 2011.
    1. Al-Rashid M, Khan WS. Stem cells and ligament repair. In: Berhardt LV, editor. Advances in Medicine and Biology. New York, NY, USA: Nova Science; 2011. pp. 343–347.
    1. Eli N, Oragui E, Khan WS. Advances in meniscal tissue engineering. Ortop Traumatol Rehabil. 2011;13(4):319–326.
    1. Khaled EG, Saleh M, Hindocha S, Griffin M, Khan WS. Tissue engineering for bone production—stem cells, gene therapy and scaffolds. The Open Orthopaedics Journal. 2011;5(2):289–295.
    1. Khan WS, Longo UG. ACI and MACI procedures for cartilage repair utilise mesenchymal stem cells rather than chondrocytes. Medical Hypotheses. 2011;77(2)
    1. Al-Rashid M, Khan WS. The role of stem cells in ligament repair. Stem Cell Research. In press.
    1. Perera JR, Jaiswal PK, Khan WS. Advances in the role of stem cells in cartilage repair. Stem Cell Research. In press.
    1. Thanabalasundaram G, Arumalla N, Tailor HD, Khan WS. Regulation of differentiation of mesenchymal stem cells into musculoskeletal cells. Current Stem Cell Research & Therapy. In press.
    1. Mohal JS, Tailor HD, Khan WS. Sources of adult mesenchymal stem cells and their applicability for musculoskeletal applications. Current Stem Cell Research & Therapy. In press.
    1. Chimutengwende-Gordon M, Khan WS. Advances in the use of stem cells and tissue engineering applications in bone repair. Current Stem Cell Research & Therapy. In press.
    1. Shekkeris AS, Jaiswal PK, Khan WS. Clinical applications of mesenchymal stem cells in the treatment of fracture non-union and bone defects. Current Stem Cell Research & Therapy. In press.
    1. Perera JR, Jaiswal PK, Khan WS. The potential therapeutic use of stem cells in cartilage repair. Current Stem Cell Research & Therapy. In press.
    1. Malvankar SM, Khan WS. An overview of the different approaches used in the development of meniscal tissue engineering. Current Stem Cell Research & Therapy. In press.
    1. Longo UG, Berton A, Khan WS, Maffulli N, Denaro V. Synthetic augmentation for massive rotator cuff tears. Sports Medicine and Arthroscopy. 2011;57:168–177.
    1. Newton Ede MP, Khan WS. The challenges of cartilage repair and the potential of stem cell applications. Journal of Stem Cells. In press.
    1. Siddiqui NA, Wong JML, Khan WS, Hazlerigg A. Stem cells for tendon and ligament tissue engineering and regeneration. Journal of Stem Cells. In press.
    1. Donaldson J, Khan WS, Hazlerigg A. Functional tissue engineering for rotator cuff tendons. Journal of Stem Cells. In press.
    1. Jaiswal PK, Wong K, Khan WS. Operative treatment of knee cartilage injuries: a review of the current literature on non-cell-based and cell-based therapies. British Journal of Medicine and Medical Research. 2011;1(4):S16–S37.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera